-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

634.O2.6 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Treatment and Outcomes in MPNs

Symposia: Myeloproliferative Syndromes: Clinical and Epidemiological Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, clinical trials, Biological therapies, Clinical Research, Chronic Myeloid Malignancies, Diseases, Therapies, Immunotherapy, Myeloid Malignancies
Monday, December 11, 2023: 10:30 AM-12:00 PM
Ballroom 20CD (San Diego Convention Center)
Moderators:
Lynda Foltz, MD, University of British Columbia and Steffen Koschmieder, University Hospital of Aachen
Disclosures:
Foltz: Amgen: Other: Spouse is an employee and holds equity and stock options. ; Incyte: Consultancy, Research Funding; PharmaEssentia: Research Funding; CTI Biopharma: Research Funding; BMS: Honoraria, Research Funding; Constellation: Research Funding; GSK: Consultancy, Research Funding; Novartis: Consultancy, Honoraria. Koschmieder: Geron: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel/accommodation support, Research Funding; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel/accommodation support, Research Funding; AOP Pharma: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel/accommodation support, Research Funding; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel/accommodation support, Research Funding; Pfizer: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel/accommodation support; Incyte: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel/accommodation support; Ariad: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Bristol Meyers Squibb: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel/accommodation support; Squibb: Consultancy, Honoraria; CTI Biopharma: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel/accommodation support; Roche: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel/accommodation support; Bayer: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; PharmaEssentia: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; RWTH Aachen University: Patents & Royalties: patent issued for a BET inhibitor; AbbVie: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel/accommodation support; Sierra Oncology: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel/accommodation support; Karthos: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel/accommodation support; Imago Bioscience: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; BMS/Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel/accommodation support; Geron, Janssen, AOP Pharma, Novartis: Research Funding; Pfizer, Incyte, Ariad, Novartis, AOP Pharma, Bristol Myers Squibb, Celgene, Geron, Janssen, CTI BioPharma, Roche, Bayer, GSK, Protagonist, MPN Hub, Bedrock, PharmaEssentia: Consultancy; Novartis, BMS/Celgene, Pfizer, Incyte, AOP Orphan, GSK, AbbVie, MPN Hub, Bedrock, iOMEDICO: Honoraria; Alexion, Novartis, Bristol Myers Squibb, Incyte, AOP Pharma, CTI BioPharma, Pfizer, Celgene, Janssen, Geron, Roche, AbbVie, GSK, Sierra Oncology, Kartos, Imago Biosciences, MSD, iOMEDICO: Other: Travel/accommodation support; RWTH Aachen University: Patents & Royalties: BET inhibitor; Pfizer, Incyte, Ariad, Novartis, AOP Pharma, BMS, Celgene, Geron, Janssen, CTI BioPharma, Roche, Bayer, GSK, Sierra Oncology, AbbVie, Protagonist, PharmaEssentia: Other: Advisory board; Protagonist: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel/accommodation support; GSK: Membership on an entity's Board of Directors or advisory committees, Other: travel/accommodation support.
This session explores treatment of classic and rare myeloproliferative neoplasms (MPN) with both established and novel therapies. Hydroxyurea and pegylated interferon are common first line treatments for MPN, each with potential advantages and disadvantages. The DALIAH study reports long term outcomes of MPN patients randomized to hydroxyurea vs pegylated interferon, providing additional information regarding molecular response rates and adverse events to assist in treatment selection. But do these results apply to younger patients? Separately, a large cohort of young adults < 25 years old with essential thrombocythemia (ET) and polycythemia vera (PV) is followed for impact of cytoreduction on long term clinical outcomes including thrombosis and progression to myelofibrosis. Novel therapies include hepcidin mimetic rusfertide in PV and the LSD-1 inhibitor bomedemstat in ET. In mastocytosis, the KIT inhibitor bezuclastinib shows efficacy and safety in patients with indolent mastocytosis. In myeloid neoplasms with eosinophilia, a custom NGS panel is used to explore the molecular landscape in patients negative for tyrosine kinase fusion genes, identifying recurrent JAK/STAT mutations associated with response to JAK inhibitors.
10:30 AM

Ellen K. Ritchie, MD1, Kristen Marie Pettit, MD2, Andrew T. Kuykendall, MD3, Marina Kremyanskaya, MD, PhD4, Naveen Pemmaraju, MD5, Sarita Khanna, PhD6*, Arturo Molina, MD, MS, FACP6 and Suneel Gupta, PhD6

1Weill Cornell Medical College, Cornell University, New York, NY
2Rogel Cancer Center, University of Michigan, Ann Arbor, MI
3Moffitt Cancer Center, Tampa, FL
4Division of Hematology & Medical Oncology, Tisch Cancer Institute/ Icahn School of Medicine at Mount Sinai, New York, NY
5Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
6Protagonist Therapeutics, Inc., Newark, CA

10:45 AM

Trine Alma Knudsen, MD1, Dennis Lund Hansen2,3*, Lukas Frans Ocias2*, Ole Bjerrum4*, Mette Brabrand2*, Sarah Friis Christensen5*, Christina Schjellerup Eickhardt-Dalbøge5*, Christina Ellervik6,7,8,9,10*, Daniel El Fassi4*, Mikael Frederiksen11*, Lasse Kjær5*, Thomas Kielsgaard Kristensen12*, Torben A. Kruse13*, Morten Kranker Larsen5*, Torben Mourits-Andersen14*, Sören Möller15*, Ulrik Malthe Overgaard4*, Marianne Tang Severinsen16*, Vibe Skov5*, Anders Lindholm Sørensen5*, Jesper Stentoft17*, Jørn Starklint18*, Karin de Stricker12*, Mads Thomassen13*, Thomas S. Larsen2,3* and Hans C. Hasselbalch5*

1Department of Hematology, Zealand University Hospital, Vaerloese, Denmark
2Department of Hematology, Odense University Hospital, Odense, Denmark
3Department of Clinical Research, University of Southern Denmark, Odense, Denmark
4Department of Hematology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
5Department of Hematology, Zealand University Hospital, Roskilde, Denmark
6Department of Pathology, Harvard Medical School, Boston, MA
7Department of Laboratory Medicine, Boston Children’s Hospital, Boston, MA
8Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
9Department of Production, Research, and Innovation, Region Zealand, Soroe, Denmark
10Department of Data Support, Region Zealand, Soroe, Denmark
11Department of Hematology, University Hospital of Southern Denmark, Aabenraa, Denmark
12Department of Pathology, Odense University Hospital, Odense, Denmark
13Department of Clinical Genetics, Odense University Hospital, Odense, Denmark
14Department of Hematology, Hospital of South West Jutland, Esbjerg, Denmark
15Research Unit of OPEN – Open Patient data Explorative Network, Odense University Hospital and University of Southern Denmark, Odense, Denmark
16Department of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark
17Department of Hematology, Aarhus University Hospital, Aarhus, Denmark
18Department of Internal Medicine, Section for Hematology, Regional Hospital West Jutland, Herning, Denmark

11:00 AM

Joachim R. Goethert, MD1, Harinder Gill, MD, MBBS, FRCP, FRCPath2, Francesca Palandri, MD3*, David M. Ross, MBBS, PhD, FRACP, FRCPA4*, Tara Cochrane, MBBS, FRCPA, FRACP5, Stephen R. Larsen6*, Anna B. Halpern, MD7, Jake Shortt8*, James M. Rossetti9*, James Liang, FRACP, FRCPA10*, Monia Marchetti, MD, PhD11*, Andrew J. Wilson, PhD, BSc, MBBS, MRCP, MSc12,13*, Andrew Innes, MD, PhD14*, Merit Hanna15*, William S. Stevenson16*, Alessandro M. Vannucchi, MD17,18*, Maria Kleppe19*, Georges Natsoulis19*, Claire N Harrison20 and Hugh Young Rienhoff Jr., MD19

1Department of Hematology and Stem Cell Transplantation, West German Cancer Center (WTZ), University Hospital Essen, Essen, Germany
2Medicine, The University of Hong Kong, Hong Kong, China
3Institute of Hematology “L. and A. Seràgnoli”, Sant'Orsola-Malpighi University Hospital, Bologna, Italy
4Department of Haematology, Royal Adelaide Hospital and SA Pathology, Adelaide, Australia
5Department of Haematology, Gold Coast University Hospital, Southport, Australia
6Institute of Haematology, Royal Prince Alfred Hospital, Sydney, Australia
7University of Washington, Seattle, WA
8Monash Haematology, Monash Health, Clayton, Australia
9Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA
10Middlemore Clinical Trials, Auckland, New Zealand
11Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo, ALESSANDRIA, Italy
12Department of Haematology, University College Hospital, University College of London Hospitals NHS Foundation Trust, London, United Kingdom
13University College London Hospitals NHS Foundation Trust, London, United Kingdom
14Centre for Haematology, Imperial College Healthcare NHS, London, United Kingdom
15Waitemata District Health Board, North Shore Hospital, Auckland, New Zealand
16Kolling Institute of Medical Research, Royal North Shore Hospital, Sydney, Australia
17University of Florence, CRIMM, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy
18CRIMM, Center for Research and Innovation of Myeloproliferative Neoplasms, University of Florence, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy
19Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., Rahway, NJ
20Guy's and St Thomas’ NHS Foundation Trust, London, ENG, United Kingdom

11:15 AM

Yan Beauverd1*, Jean-Christophe Ianotto, MD, PhD2*, Kyaw Htin Thaw3*, Marta Sobas, MD, PhD4*, Parvis Sadjadian5*, Natalia Curto-Garcia6*, Lee-Yung Shih, MD7, Timothy Devos, MD8*, Dorota Krochmalczyk, MD9*, Serena Galli10*, Maria Bieniaszewska11*, Ilona Seferynska12*, Mary Frances McMullin, MD, FRCPath, FRCP13, Anna Armatys, MD14*, Adrianna Spalek14*, Joanna Waclaw, MD15*, Mihnea Tudor Zdrenghea16*, Laurence Legros, MD, PhD17*, Francois Girodon, MD, PhD18*, Krzysztof Lewandowski, MD, PhD19*, Anna Angona Figueras20*, Jan Samuelsson, MD, PhD21, Aitor Abuin Blanco22*, Pascale Cony-Makhoul, MD23*, Angela Collins, BSc, MBBS, MRCP24*, Chloe James, MD, PhD25*, Rajko Kusec, MD, PhD26*, Marie Lauermannova27*, Maria Soledad Noya28*, Malgorzata Skowronek29*, Lukasz Szukalski30*, Anna Szmigielska-Kaplon31*, Marielle Wondergem, MD, PhD32, Iryna Dudchenko, MD, PhD33*, Joanna Gora-Tybor, MD, PhD31*, Kamel Laribi34*, Anna Kulikowska De Nalecz35*, Jean-Loup Demory, MD36*, Katell Le Du, MD37*, Sonja Zweegman, MD, PhD32, Carlos Besses Raebel, MD, PhD20*, Radek C. Skoda, MD38, Stephane Giraudier39*, Martin Griesshammer5, Jean-Jacques Kiladjian, MD, PhD40 and Claire N Harrison41

1Haematology Division, Department of Oncology, Geneva University Hospitals, Geneva, Switzerland
2Centre Hospitalier Universitaire de Brest,, Brest, France
3Haematology Department, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
4Wroclaw Medical University, Wroclaw, Poland
5University Clinic for Hematology, Oncology, Hemostasis and Palliative Care, Johannes Wesling Medical Center, University of Bochum, Minden, Germany
6Haematology Department, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom, London, United Kingdom
7Division of Hematology-Oncology, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan
8Department of Hematology, University Hospitals Leuven, Leuven, Belgium
9Department of Hematology, Collegium Medicum, Jagiellonian University, Krakow, Poland
10Department of Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland
11Hematology and Transplantation Department, Medical University and Clinical Center, Gdansk, Poland
12Institute of Hematology and Transfusion Medicine, Warsaw, Poland
13Haematology, Belfast City Hospital, Queen's University Belfast, Belfast, United Kingdom
14Hematology Department, Jagiellonian University Hospital, Krakow, Poland
15Department of Hematology, Collegium Medicum, Jagiellonian University, Kraków, Poland
16Iuliu Hatieganu University of Medicine and Pharmacy, Department of Hematology, Cluj-Napoca, Romania
17Hematology Department, AP-HP, University of Paris Saclay, Bicêtre Hospital, Paris, France
18Laboratory of Biological Hematology, University Hospital, Dijon, France
19Hematology and Bone Marrow Transplantation Department, University of Medical Sciences, Poznan, Poland
20Hematology Department, Hospital del Mar, Barcelona, Spain
21Hematology Department, University Hospital, Linkoping, Sweden
22Servicio de Hematología. Hospital Universitario Lucus Augusti, Lugo, Spain
23Department of Hematology, Annecy-Genevois Hospital Centre, Pringy, France
24Department of Haematology, Norfolk and Norwich University Hospitals National Health Service Trust, Norwich, United Kingdom
25Biology of Cardiovascular Diseases, University of Bordeaux, INSERM, UMR1034, Pessac, France
26Department of Hematology, University Hospital Dubrava, School of Medicine, University of Zagreb, Zagreb, Croatia
27Institute of Hematology and Blood Transfusion, Prague, Prague, Czech Republic
28Hematology Department, University Hospital Juan Canalejo-CHUAC, La Coruña, Spain
29Department of Hematology, Holy Cross Oncology Center,, Kielce, Poland
30Nicolaus Copernicus University in Torun Ludwik Rydygier, Collegium Medicum in Bydgoszcz, Bydgoszcz, Poland
31Department of Hematology, Medical University, Lodz, Poland
32Department of Hematology, Amsterdam University Medical Centers, Amsterdam, Netherlands
33Sumy State University, Medical institute, Department of Internal Medicine with Respiratory Medicine Center, Sumy, Ukraine
34Hematology Department, Le Mans Hospital, Le Mans, France
35Department of Hematology, State Hospital, Opole, Poland
36Department of Hematology, St. Vincent De Paul Hospital, Lille, France
37The Confluent, Private Hospital, Nantes, France
38Experimental Hematology, Department of Biomedicine, University Hospital and University, Basel, Switzerland
39Cellular Biology Department, INSERM UMRS 1131, St Louis Hospital, APHP, Paris, France
40Hopital Saint-Louis, Paris, France
41Guy’s and St. Thomas’ NHS Foundation Trust, London, ENG, United Kingdom

11:30 AM

Deepika Dilip, MPH1*, Kamal Menghrajani, MD2, Jacob Glass, MD, PhD3, Raajit K. Rampal, MD, PhD4, Christopher Famulare, MS5*, Maria Sirenko, PhD6, Ross L Levine, MD7 and Richard Koche, PhD8*

1New York Medical College, Valhalla, NY
2MSKCC Memorial Sloan Kettering Cancer Center, New York, NY
3Leukemia Service, Department of Medicine, Center for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, NY
4Memorial Sloan Kettering Cancer Center, New York, NY
5Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY
6Laura & Isaac Perlmutter Cancer Center, NYU Langone, New York, NY
7Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY
8Center for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, NY

11:45 AM

Justin M. Watts, MD1, Alessandro M. Vannucchi, MD2*, Anthony M. Hunter, MD3*, Brandon McMahon, MD4, Srinivas K. Tantravahi, MBBS5, Alessandra Iurlo, MD, PhD6*, Blanca Xicoy, MD7*, Francesca Palandri, MD8*, Emma Searle, MBChB MA MRCP FRCPath PhD9*, Brandi N. Reeves, MD10, Prithviraj Bose, MD11, Rosa Ayala, MD, PhD12*, Anna B. Halpern, MD13, Xuejun Chen, PhD14*, Lea M Burke, MS14*, Feng Zhou, PhD14*, Fred Zheng, MD14* and Pankit Vachhani, MD15*

1Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, MIAMI, FL
2University of Florence, CRIMM, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy
3Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta
4University of Colorado School of Medicine, Aurora, CO
5Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, The University of Utah, Salt Lake Cty, UT
6Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
7Hematology Service, Hospital Germans Trias I Pujol, Institut Català Oncologia, Josep Carreras Leukemia Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain
8IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Bologna, Italy, Bologna, Italy
9University of Manchester, Manchester, United Kingdom
10University of North Carolina-Chapel Hill, Chapel Hill, NC
11The University of Texas MD Anderson Cancer Center, Houston, TX
12Hospital Universitario 12 De Octubre, Madrid, ESP
13University of Washington, Seattle, WA
14Incyte Corporation, Wilmington, DE
15O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham, Birmingham, AL

*signifies non-member of ASH